OncoMatch/Clinical Trials/NCT05780034
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Is NCT05780034 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies AC676 for relapsed/refractory b-cell malignancies.
Treatment: AC676 — This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: small molecule anti-cancer drug
Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days)
Cannot have received: systemic chemotherapy
Systemic chemotherapy within 14 days
Cannot have received: radiation therapy
Radiation therapy within 14 days
Cannot have received: biologic therapy
Biologics (Antibodies) treatment within 28 days
Cannot have received: radioimmunoconjugate or toxin conjugate
Radioimmunoconjugates or toxin conjugates within 12 weeks
Cannot have received: CAR-T cell therapy
Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.
Cannot have received: autologous or allogenic stem cell transplant
Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute · Denver, Colorado
- Florida Cancer Specialists · Sarasota, Florida
- University of North Carolina · Chapel Hill, North Carolina
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- The Ohio State University - The James Cancer Hospital and Solove Research Institute · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05780034 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior small molecule anti-cancer drug, systemic chemotherapy, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify